Characteristics of 6 End-Stage Cancer Patients Treated with Fractionated 213Bi-FAPI-46 RPT
| Patient | Age (y) | Sex | Primary tumor | Metastatic lesions | Previous therapies | Concomitant therapy | RPT injections (n) | Duration (h) | Total activity of 213Bi-FAPI-46 (MBq) | Response |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 63 | M | Adenocarcinoma of ascending colon | Liver, LNs, lung, soft tissue | S, FOLFIRI–avastin, FOLFOX–bevacizumab, RT | Pembrolizumab | 8 | 95 | 1,474 | PD |
| 2 | 49 | F | Triple-negative adenocarcinoma of breast | Bone, LNs, lung, pleura | Epirubicin–cyclophosphamide, paclitaxel, S, RT, capecitabine, carboplatin | Pembrolizumab | 9 | 102 | 1,708 | PD |
| 3 | 46 | F | Anal squamous cell carcinoma | Bone, liver, LNs, lung, peritoneum | RCT, S, cisplatin–capecitabine, nivolumab–avastin–ipilimumab, RT, avastin–endoxan, FOLFOX | Pembrolizumab | 11 | 107 | 1,957 | SD |
| 4 | 48 | F | Adenocarcinoma of sigmoid colon | Bone, LNs, pleura | S, FOLFOX, FOLFIRI–panitumumab, ipilimumab–nivolumab–maraviroc, RT, avastin | None | 8 | 26 | 1,634 | PD |
| 5 | 77 | M | PSMA-negative adenocarcinoma of prostate | Bone, LNs | Taxane-based chemotherapy, enzalutamide, abiraterone | None | 12 | 103 | 1,954 | PR |
| 6 | 16 | F | Signet ring cell carcinoma of colon | LNs, peritoneum, stomach | S, FOLFIRI–avastin, FOLFOX–bevacizumab, FOLFIRI–avastin, HIPEC | Pembrolizumab | 5 | 95 | 925 | PD |
LNs = lymph nodes; S = surgery; FOLFIRI = folinic acid, fluorouracil, and irinotecan hydrochloride; FOLFOX = folinic acid, fluorouracil, and oxaliplatin; RT = radiotherapy; PD = progressive disease; RCT = radiochemotherapy; SD = stable disease; PR = partial remission; HIPEC = hyperthermic intraperitoneal chemotherapy.